



Short Communication

Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19 Insights from the Cardio-COVID-Italy multicenter study



Matteo Pagnesi^a, Riccardo M. Inciardi^a, Carlo M. Lombardi^a, Piergiuseppe Agostoni^{b,c}, Pietro Ameri^d, Lucia Barbieri^e, Antonio Bellasi^f, Rita Camporotondo^g, Claudia Canale^d, Valentina Carubelli^a, Stefano Carugo^{h,i}, Francesco Catagnano^{g,j}, Laura A. Dalla Vecchia^k, Gian Battista Danzi^l, Mattia Di Pasquale^a, Margherita Gaudenzi^{b,c}, Stefano Giovinazzo^d, Massimiliano Gnechi^g, Marco Guazzi^{m,n}, Annamaria Iorio^o, Maria Teresa La Rovere^p, Sergio Leonardi^g, Gloria Maccagni^l, Massimo Mapelli^{b,c}, Davide Margonato^{g,j}, Marco Merlo^q, Luca Monzo^r, Andrea Mortara^j, Vincenzo Nuzzi^q, Massimo Piepoli^{s,t}, Italo Porto^d, Andrea Pozzi^o, Filippo Sarullo^u, Gianfranco Sinagra^q, Chiara Tedino^a, Daniela Tomasoni^a, Maurizio Volterrani^v, Gregorio Zaccone^a, Michele Senni^o, Marco Metra^{a,*}

^a Institute of Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy

^b Centro Cardiologico Monzino, IRCCS, Milan, Italy

^c Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

^d IRCCS Ospedale Policlinico San Martino and Department of Internal Medicine, University of Genova, Genova, Italy

^e Division of Cardiology, Ospedale San Paolo, ASST Santi Paolo e Carlo, Milan, Italy

^f Innovation and Brand Reputation Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy

^g Intensive Cardiac Care Unit, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy

^h Division of Cardiology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

ⁱ University of Milan, Milan, Italy

^j Cardiology Department, Policlinico di Monza, Monza, Italy

^k Cardiology Department, IRCCS Istituti Clinici Scientifici Maugeri, Istituto Scientifico di Milano, Milan, Italy

^l Division of Cardiology, Ospedale Maggiore di Cremona, Cremona, Italy

^m Heart Failure Unit, Cardiology Department, University of Milan, Milan, Italy

ⁿ IRCCS San Donato Hospital, Milan, Italy

^o Cardiovascular Department and Cardiology Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy

^p Cardiology Department, IRCCS Istituti Clinici Scientifici Maugeri, Istituto Scientifico di Pavia, Pavia, Italy

^q Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, Trieste, Italy

^r Istituto Clinico Casalpalocco and Policlinico Casilino, Rome, Italy

^s Heart Failure Unit, Guglielmo da Saliceto Hospital, AUSL Piacenza, Piacenza, Italy

^t Institute of Life Sciences, Sant'Anna School of Advanced Studies, Pisa, Italy

^u Cardiovascular Rehabilitation Unit, Buccheri La Ferla Fatebenefratelli Hospital, Palermo, Italy

^v Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy

ARTICLE INFO

Article history:

Received 20 February 2021

Received in revised form 18 May 2021

Accepted 21 May 2021

Keywords:

COVID-19

ABSTRACT

Background: Glucocorticoid therapy has emerged as an effective therapeutic option in hospitalized patients with coronavirus disease 2019 (COVID-19). This study aimed to focus on the impact of relevant clinical and laboratory factors on the protective effect of glucocorticoids on mortality.

Methods: A sub-analysis was performed of the multicenter Cardio-COVID-Italy registry, enrolling consecutive patients with COVID-19 admitted to 13 Italian cardiology units between 01 March 2020 and 09 April 2020. The primary endpoint was in-hospital mortality.

Results: A total of 706 COVID-19 patients were included (349 treated with glucocorticoids, 357 not treated

* Corresponding author at: Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

E-mail address: metramarco@libero.it (M. Metra).

SARS-CoV-2
Glucocorticoid
Corticosteroid
Steroid

with glucocorticoids). After adjustment for relevant covariates, use of glucocorticoids was associated with a lower risk of in-hospital mortality (adjusted HR 0.44; 95% CI 0.26–0.72; p = 0.001). A significant interaction was observed between the protective effect of glucocorticoids on mortality and PaO₂/FiO₂ ratio on admission (p = 0.042), oxygen saturation on admission (p = 0.017), and peak CRP (0.023). Such protective effects of glucocorticoids were mainly observed in patients with lower PaO₂/FiO₂ ratio (<300), lower oxygen saturation (<90%), and higher CRP (>100 mg/L).

Conclusions: The protective effects of glucocorticoids on mortality in COVID-19 were more evident among patients with worse respiratory parameters and higher systemic inflammation.

© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and represents a major cause of morbidity and mortality worldwide (Wiersinga et al., 2020). Systemic glucocorticoids have emerged as an effective therapeutic option in hospitalized patients with COVID-19, especially in cases of moderate-severe acute respiratory distress

syndrome or need of respiratory support (RECOVERY Collaborative Group et al., 2021; Tomazini et al., 2020; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al., 2020). However, their use may be associated with drug-related adverse events (e.g., potential pro-thrombotic effect, increased susceptibility to infection, neuro-psychiatric symptoms, etc.) that could be detrimental in patients with COVID-19 (Mishra and Mulani, 2021). Hence, further assessment of the subset of patients most

Table 1
Baseline clinical characteristics, clinical presentation, laboratory data, and in-hospital management.

	No glucocorticoids (n = 357)	Glucocorticoids (n = 349)	p-Value
<i>Baseline characteristics</i>			
Age (years)	68.1 ± 13.8	66.9 ± 12.3	0.22
Male sex	243 (68.1%)	247 (70.8%)	0.44
BMI (kg/m ²)	26.7 ± 5.2	27.8 ± 5.1	0.011
Smoking	84 (29.2%)	77 (25.6%)	0.33
Hypertension	200 (56.5%)	202 (58.2%)	0.65
Dyslipidemia	97 (27.4%)	96 (27.7%)	0.92
Diabetes mellitus	89 (25.1%)	75 (21.6%)	0.27
Atrial fibrillation	67 (18.9%)	41 (11.8%)	0.009
Coronary artery disease	83 (23.4%)	66 (19.0%)	0.15
History of HF	58 (16.4%)	36 (10.4%)	0.020
COPD	37 (10.5%)	31 (8.9%)	0.50
CKD	71 (20.1%)	59 (17.0%)	0.30
History of neoplasia	32 (9.0%)	26 (7.5%)	0.46
<i>Clinical presentation (hospital admission)</i>			
Fever	213 (60.0%)	241 (69.3%)	0.010
Respiratory rate ≥ 22 bpm	110 (45.8%)	174 (56.7%)	0.012
Systolic blood pressure (mmHg)	129.5 ± 21.6	130.0 ± 21.6	0.74
Diastolic blood pressure (mmHg)	74.4 ± 13.2	75.1 ± 12.9	0.53
Heart rate (bpm)	86.5 ± 18.0	86.8 ± 18.0	0.83
Oxygen saturation (%)	92.1 ± 6.3	88.8 ± 8.6	< 0.001
PaO ₂ /FiO ₂ ratio	269.7 ± 133.4	201.9 ± 120.5	< 0.001
SOFA score ≥ 3	85 (38.5%)	111 (47.2%)	0.06
<i>Laboratory data</i>			
Increased troponin	158 (45.9%)	121 (44.0%)	0.63
Hemoglobin (g/dL)	12.9 [11.6, 14.1]	13.7 [12.1, 14.6]	< 0.001
WBC count (per μL)	6820 [5100, 9150]	6610 [4890, 9550]	0.88
Lymphocyte count (per μL)	1015 [700, 1490]	840 [570, 1100]	< 0.001
Platelet count (10 ⁹ /L)	210 [159, 280]	198 [150, 257]	0.06
Creatinine (mg/dL)	1.0 [0.8, 1.4]	1.0 [0.8, 1.2]	0.14
eGFR (mL/min/1.73 m ²)	71.6 [45.6, 89.0]	77.1 [55.7, 90.6]	0.07
CRP on admission (mg/L)	40 [6, 100]	66 [21, 154]	< 0.001
Peak CRP (mg/L)	84 [21, 153]	110 [44, 210]	< 0.001
D-dimer (ng/mL)	743 [358, 1703]	930 [473, 1686]	0.024
Serum ferritin (ng/mL)	623 [332, 1321]	802 [429, 1550]	0.13
NT-proBNP (pg/mL)	392 [111, 2584]	230 [83, 940]	0.06
Lactate dehydrogenase (U/L)	340 [241, 505]	379 [273, 531]	0.14
<i>In-hospital management</i>			
No oxygen support	89 (25.6%)	28 (8.2%)	< 0.001
Oxygen support with FiO ₂ ≥ 50%	138 (39.7%)	245 (71.4%)	< 0.001
Non-invasive ventilation	88 (24.8%)	215 (62.1%)	< 0.001
Intubation (invasive ventilation)	34 (9.6%)	74 (21.3%)	< 0.001
<i>Antiviral therapy</i>			
Lopinavir/ritonavir	114 (31.9%)	75 (21.5%)	0.002
Darunavir/ritonavir	83 (23.3%)	93 (26.7%)	0.30
Remdesivir	4 (1.1%)	1 (0.3%)	0.19

Data are presented as n/N (%), mean standard deviation or median [Q25, Q75]. Significant p-values are reported in bold. Abbreviations: BMI, body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HF, heart failure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SOFA, Sequential Organ Failure Assessment; WBC, white blood cell.




Figure 1. The association between glucocorticoid treatment effect on in-hospital mortality and PaO₂/FiO₂ ratio on admission, oxygen saturation on admission, and peak C-reactive protein (CRP). The hazard ratio (HR) and 95% confidence interval (CI) are shown across the spectrum of the continuous variables of interest (PaO₂/FiO₂ ratio on admission, oxygen saturation on admission, and peak CRP); p-values for interaction between glucocorticoid use and the continuous variables of interest are also reported.

responsive to glucocorticoids could be useful to refine the use of these drugs in hospitalized patients with COVID-19. This study aimed to confirm the protective effect of glucocorticoid use on mortality in a real-world, inpatient COVID-19 population, and to focus on the impact of relevant clinical and laboratory factors on such protective effect.

Methods

A multicenter registry of consecutive patients with laboratory-confirmed COVID-19 and admitted to 13 Italian cardiology units

between 01 March and 09 April 2020 was analyzed. Details on study design and study population have already been described (Lombardi et al., 2020; Tomasoni et al., 2020). Baseline characteristics, laboratory data, and details on clinical presentation, in-hospital management, and in-hospital outcomes were compared between patients who received vs. those who did not receive systemic glucocorticoids during hospital stay. The association between glucocorticoid use and in-hospital mortality was assessed by means of univariate and multivariate Cox regression analysis; the results are presented as hazard ratio (HR) and 95% confidence interval (CI). Kaplan–Meier analysis was also performed to report the estimated rate of in-hospital mortality and to compare mortality between groups (log-rank test). The interaction between glucocorticoid use and several variables of interest with respect to in-hospital mortality was tested by means of formal interaction testing analysis; the relationship between the levels of continuous variables of interest and the treatment effect of glucocorticoids (HR for in-hospital mortality) was displayed using restricted cubic spline models. A p-value < 0.05 (two-tailed) was considered statistically significant. All statistical analyses were performed using Stata version 14 (Stata Corp., College Station, Texas).

Results and discussion

A total of 706 patients were included in the present analysis (349 treated with glucocorticoids and 357 not treated with glucocorticoids). Mean age was 68 ± 13 years, and 69.4% of patients were male. As shown in Table 1, patients treated with glucocorticoids had higher body mass index (BMI) and less frequently reported a history of heart failure (HF) or atrial fibrillation (AF), as compared with patients not treated with glucocorticoids. At clinical presentation, oxygen saturation and PaO₂/FiO₂ ratio were significantly lower and the presence of fever and respiratory rate ≥ 22 bpm was more frequent in the glucocorticoids group. Regarding laboratory findings at hospital admission, patients treated with glucocorticoids had significantly lower levels of lymphocytes and higher levels of hemoglobin, C-reactive protein (CRP), and D-dimer; furthermore, peak CRP during hospital stay was significantly higher in the glucocorticoids group. During hospital stay, oxygen support with FiO₂ $\geq 50\%$, non-invasive ventilation, and intubation were more frequent in the glucocorticoids group, whereas patients not treated with glucocorticoids more frequently did not receive oxygen support (Table 1). Median hospital stay in the overall population was 14 [interquartile range 9–24] days, and a total of 166 patients (23.5%) died during hospital stay (78 in the glucocorticoid group, 88 in the no glucocorticoid group). Glucocorticoid use was associated with lower in-hospital all-cause mortality (HR 0.61; 95% CI 0.45–0.83; $p = 0.002$). Kaplan–Meier estimated rates of cumulative 28-day mortality were 38.0% and 45.2% in the glucocorticoids and no glucocorticoids groups, respectively (log-rank $p = 0.001$; Supplementary Figure 1). After adjustment for age, participating center, hypertension, AF, coronary artery disease, history of HF, chronic kidney disease, PaO₂/FiO₂ ratio, increased troponin, peak CRP, lymphocyte count, and hemoglobin values, glucocorticoid use remained independently associated with lower in-hospital mortality (adjusted HR 0.44; 95% CI 0.26–0.72; $p = 0.001$). The Harrel’s C-index for the multivariable model was 0.80 (95% CI 0.75–0.85). With respect to in-hospital mortality, a significant interaction was observed between glucocorticoid use and PaO₂/FiO₂ ratio on admission ($p = 0.042$), oxygen saturation on admission ($p = 0.017$), and peak CRP ($p = 0.023$), but not BMI ($p = 0.282$), history of HF ($p = 0.733$), AF ($p = 0.836$), coronary artery disease ($p = 0.577$), hemoglobin ($p = 0.794$), lymphocyte count ($p = 0.274$), increased troponin ($p = 0.527$), D-dimer on admission ($p = 0.450$), and CRP on admission ($p = 0.478$). As shown in Figure 1, the protective effect of glucocorticoids on

mortality was mainly observed in patients with lower values of PaO₂/FiO₂ ratio on admission (<300), lower values of oxygen saturation on admission (<90%), and higher values of peak CRP (>100 mg/L).

In line with recent studies reporting lower mortality in COVID-19 patients treated with glucocorticoids only in case of need of oxygen therapy or mechanical ventilation (RECOVERY Collaborative Group et al., 2021), this analysis showed a significant interaction between the protective effect of glucocorticoids on mortality and levels of PaO₂/FiO₂ ratio and oxygen saturation on admission. Furthermore, such protective effect was more pronounced in patients with higher values of peak CRP during hospital stay, which is similar to a recent study reporting benefit of early glucocorticoid use only in patients with CRP ≥ 200 mg/L and harm in patients with CRP < 100 mg/L (Keller et al., 2020). Of note, the protective effects of glucocorticoids could not merely be a class-effect, but may depend also on duration of therapy and the type of drug used, as suggested by the conflicting results of the RECOVERY trial with dexamethasone and the Metcovid trial with methylprednisolone (Jeronimo et al., 2021; RECOVERY Collaborative Group et al., 2021). Unfortunately, details on type and doses of glucocorticoids and duration of therapy were not available in the current registry, and data on glucocorticoid therapy prior to hospital admission, pre-existing autoimmune or rheumatological diseases, and time from symptom onset to hospital admission were not collected. Considering the potential glucocorticoid-related adverse events, a detailed assessment of risk-benefit ratio and the identification of patients most responsive to such therapy are fundamental. Future, larger studies are needed to further refine the use of glucocorticoids in patients with COVID-19.

Disclosures

Dr. Agostoni received non-financial support from Menarini, Novartis, and Boehringer; grants from Daiichi Sankyo and Bayer; and grants and non-financial support from Actelion. Dr. Ameri received speaker and advisor honoraria from Novartis, AstraZeneca, Vifor, Daiichi-Sankyo, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, and Merck, Sharp & Dohme; and non-financial support from Actelion. Dr. Carubelli received consulting honoraria from CVie Therapeutics Limited, Servier, and Windtree Therapeutics. Dr. Leonardi received grants and personal fees from AstraZeneca; and personal fees from BMS/Pfizer, Novo Nordisk, and Chiesi. Dr. Mortara received personal consulting honoraria from Novartis, Servier, Astra Zeneca for participation to advisory board meetings; and receives grants from Novartis and Niccomo for research trials. Dr. Piepoli received research grant and speaking fees from Novartis, Servier, and TRX; and non-financial support from Vifor. Dr. Senni reported personal fees from Novartis, Abbott, Merck, Bayer, Boehringer, Vifor, and AstraZeneca. Dr. Metra received personal consulting honoraria from Abbott, Actelion,

Amgen, Bayer, Edwards Therapeutics, Servier, Vifor Pharma, and Windtree Therapeutics for participation to advisory board meetings and executive committees of clinical trials. All other authors have no conflicts of interest to disclose.

Funding source

No funding was provided for this study.

Ethical approval

This study complied with the edicts of the Declaration of Helsinki and was approved by the ethical committee of Civil Hospitals of Brescia Italy (no. NP 4105) and of each recruiting center.

Acknowledgements

None.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.ijid.2021.05.056>.

References

- Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. *Clin Infect Dis* 2021;72:e373–81.
- Keller MJ, Kitsis EA, Arora S, Chen J-T, Agarwal S, Ross MJ, et al. Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. *J Hosp Med* 2020;15:489–93.
- Lombardi CM, Carubelli V, Iorio A, Inciardi RM, Bellasi A, Canale C, et al. Association of troponin levels with mortality in Italian patients hospitalized with coronavirus disease 2019: results of a multicenter study. *JAMA Cardiol* 2020;5:1274–80.
- Mishra GP, Mulani J. Corticosteroids for COVID-19: the search for an optimum duration of therapy. *Lancet Respir Med* 2021;9:e8.
- RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med* 2021;384:693–704.
- Tomasoni D, Inciardi RM, Lombardi CM, Tedino C, Agostoni P, Ameri P, et al. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study. *Eur J Heart Fail* 2020;22:2238–47.
- Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. *JAMA* 2020;324:1307–16.
- WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. *JAMA* 2020;324:1330–41.
- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. *JAMA* 2020;324:782–93.